CoChat

Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy

Valecha, Gautam Kishore, Vennepureddy, Adarsh, Ibrahim, Uroosa, Safa, Firas, Samra, Bachar, Atallah, Jean Paul · 2017 · Expert Review of Anticancer Therapy
Cited by 38

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Advanced non-small cell lung cancer (NSCLC) has been conventionally treated with cytotoxic chemotherapy with short-lived responses and significant toxicities. Monoclonal antibodies to programmed death-1 receptor (PD-1) and programmed death ligand 1 (PD-L1) have shown tremendous promise in the treatment of advanced NSCLC in various clinical trials. Areas covered: In this article, we will review the outcomes of various trials of anti-PD-1/anti-PD-L1 antibodies in the treatment of NSCLC. We will also discuss their mechanism of action and toxicities. Expert commentary: Anti-PD-1/PD-L1 antibodies offer several advantages including significant antitumor activity, induction of long lasting responses, and favorable safety profile. Several trials are now being conducted to evaluate their efficacy as first line agents as well as in combination with other agents. More research is also needed to identify other biomarkers, in addition to PD-L1 expression, that could more reliably predict response to these drugs, and aid in better patient selection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/14737140.2017.1259574

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 38

Metadata

Authors
Valecha, G. K., Vennepureddy, A., Ibrahim, U., Safa, F., Samra, B., & Atallah, J. P.
Venue
Expert Review of Anticancer Therapy
Published
2016-11-23
Volume
17
Issue
1
Pages
47-59
ISSN
  • 1473-7140 (ISSN-L)
  • 1744-8328
OpenAlex
W2554978154
Cited by
38
References
7
FWCI
3.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. https://app.cochat.ai/papers/10.1080/14737140.2017.1259574
The paper
Valecha, G. K., Vennepureddy, A., Ibrahim, U., Safa, F., Samra, B., & Atallah, J. P. (2017). Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. Expert Review of Anticancer Therapy. https://doi.org/10.1080/14737140.2017.1259574

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.